Enter a phrase above to search files and articles within the site.

Typically materials that are more than 5 years old will be archived
Displaying 1 - 10 of 10 results

Polymyalgia Rheumatica

https://www.niams.nih.gov/health-topics/polymyalgia-rheumatica

What is polymyalgia rheumatica? Polymyalgia rheumatica causes muscle pain and stiffness in the neck, shoulder, and hip. The pain and stiffness usually occur in the morning or when you haven’t been moving for a while. It typically lasts longer than 30 minutes. For most people, the condition develops over time. But for some people it can start quickly – even overnight. In addition to stiffness, you may have a fever, weakness, and weight loss. Polymyalgia rheumatica usually goes away within one year, but it could last several years. People with polymyalgia rheumatica often have giant cell arteritis a disorder associated

Osteonecrosis

https://www.niams.nih.gov/health-topics/osteonecrosis

What is osteonecrosis? Osteonecrosis is a bone disease. It results from the loss of blood supply to the bone. Without blood, the bone tissue dies. This causes the bone to collapse. It may also cause the joints that surround the bone to collapse. If you have osteonecrosis, you may have pain or be limited in your physical activity. Osteonecrosis can develop in any bone, most often in the: Thigh bone (femur). Upper arm bone (humerus). Knees. Shoulders. Ankles. It is also called: Avascular necrosis. Aseptic necrosis. Ischemic necrosis.

Vitiligo

https://www.niams.nih.gov/health-topics/vitiligo

What is vitiligo? Vitiligo is a chronic (long-lasting) disorder that causes areas of skin to lose color. When skin cells that make color are attacked and destroyed, the skin turns a milky-white color. No one knows what causes vitiligo, but it may be an autoimmune disease. In people with autoimmune diseases, the immune cells attack the body’s own healthy tissues by mistake, instead of viruses or bacteria. A person with vitiligo sometimes may have family members who also have the disease. There is no cure for vitiligo, but treatment may help skin tone appear more even.

Sjögren’s Syndrome

https://www.niams.nih.gov/health-topics/sjogrens-syndrome

What is Sjögren’s syndrome? Sjögren’s syndrome is a disease that affects the glands that make moisture. It most often causes dryness in the mouth and eyes. It can also lead to dryness in other places that need moisture, such as the nose, throat, and skin. Sjögren’s syndrome is also a rheumatic disease, which affect: Joints. Tendons. Ligaments. Bones. Muscles. The signs and symptoms of rheumatic diseases can include: Redness or heat. Swelling. Pain. Loss of function. Primary Versus Secondary Sjögren’s Syndrome Doctors have two categories for Sjögren’s syndrome: Primary form: Occurs if you do not have other rheumatic diseases. Secondary

Modified Protein Improves Vitiligo Symptoms in Mice

https://www.niams.nih.gov/newsroom/spotlight-on-research/modified-protein-improves-vitiligo-symptoms-mice

Altering a key protein involved in the development of vitiligo may protect against—or even reverse—the pigmentation loss associated with the skin disorder in mice, according to recent research funded by the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases, and published in the journal Science Translational Medicine. Vitiligo is a progressive autoimmune disease in which the skin cells that impart color (melanocytes) are destroyed, resulting in white patches on the face, hands and other parts of the body. Scientists are unsure what causes vitiligo. They are investigating the biological mechanisms that trigger the disease, as well as its

Same Immune Regulatory Protein Found to Play Instrumental Role in Two Hereditary Autoinflammatory Diseases

https://www.niams.nih.gov/newsroom/spotlight-on-research/same-immune-regulatory-protein-found

Research funded in part by the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has revealed a new role for A20, a protein that regulates a key immune response pathway, in certain early-onset autoinflammatory diseases. The results suggest that targeting this pathway could be an effective strategy for treating these diseases, and possibly related conditions, as well.